S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
NASDAQ:AKRO

Akero Therapeutics - AKRO Stock Forecast, Price & News

$37.45
-2.39 (-6.00%)
(As of 03/24/2023 08:50 PM ET)
Add
Compare
Today's Range
$37.40
$39.82
50-Day Range
$37.27
$50.24
52-Week Range
$7.52
$54.88
Volume
1.07 million shs
Average Volume
596,904 shs
Market Capitalization
$1.76 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.40

Akero Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
39.9% Upside
$52.40 Price Target
Short Interest
Healthy
7.26% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.71mentions of Akero Therapeutics in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$5.16 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.95) to ($3.40) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

217th out of 995 stocks

Pharmaceutical Preparations Industry

88th out of 482 stocks


AKRO stock logo

About Akero Therapeutics (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. operates as a cardio-metabolic nonalcoholic steatohepatitis company, which engages in developing pioneering medicines designed to restore metabolic balance and improve overall health. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

Receive AKRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKRO Stock News Headlines

Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
Akero Therapeutics (NASDAQ:AKRO) Trading Down 4.3%
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
AKRO Akero Therapeutics, Inc.
AKRO.O
See More Headlines
Receive AKRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKRO Company Calendar

Last Earnings
11/12/2021
Today
3/26/2023
Next Earnings (Estimated)
5/05/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKRO
Fax
N/A
Employees
33
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$52.40
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+39.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-112,030,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.85 per share

Miscellaneous

Free Float
42,095,000
Market Cap
$1.76 billion
Optionable
Not Optionable
Beta
-0.91

Key Executives

  • Andrew ChengAndrew Cheng
    President, Chief Executive Officer & Director
  • Jonathan YoungJonathan Young
    Chief Operating Officer & Executive Vice President
  • William R. White
    CFO, Treasurer, EVP & Head-Corporate Development
  • Timothy Rolph
    Chief Scientific Officer
  • Reshma Shringarpure
    Vice President-Clinical Research & Medical Affairs













AKRO Stock - Frequently Asked Questions

Should I buy or sell Akero Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AKRO shares.
View AKRO analyst ratings
or view top-rated stocks.

What is Akero Therapeutics' stock price forecast for 2023?

4 brokerages have issued 1 year price targets for Akero Therapeutics' shares. Their AKRO share price forecasts range from $25.00 to $65.00. On average, they expect the company's stock price to reach $52.40 in the next twelve months. This suggests a possible upside of 39.9% from the stock's current price.
View analysts price targets for AKRO
or view top-rated stocks among Wall Street analysts.

How have AKRO shares performed in 2023?

Akero Therapeutics' stock was trading at $54.80 at the start of the year. Since then, AKRO stock has decreased by 31.7% and is now trading at $37.45.
View the best growth stocks for 2023 here
.

When is Akero Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023.
View our AKRO earnings forecast
.

How were Akero Therapeutics' earnings last quarter?

Akero Therapeutics, Inc. (NASDAQ:AKRO) posted its quarterly earnings data on Friday, November, 12th. The company reported ($0.70) EPS for the quarter, topping analysts' consensus estimates of ($0.91) by $0.21.

What other stocks do shareholders of Akero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Fulcrum Therapeutics (FULC), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Gossamer Bio (GOSS), Provention Bio (PRVB), Alector (ALEC), Micron Technology (MU), VIVUS (VVUS).

When did Akero Therapeutics IPO?

(AKRO) raised $75 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI acted as the underwriters for the IPO and Roth Capital Partners was co-manager.

What is Akero Therapeutics' stock symbol?

Akero Therapeutics trades on the NASDAQ under the ticker symbol "AKRO."

Who are Akero Therapeutics' major shareholders?

Akero Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Avidity Partners Management LP (8.18%), Skorpios Trust (7.00%), Alkeon Capital Management LLC (6.94%), Price T Rowe Associates Inc. MD (5.13%), Marshall Wace LLP (3.22%) and Geode Capital Management LLC (1.35%). Insiders that own company stock include Andrew Cheng, Apple Tree Partners Iv, LP, Catriona Yale, Global Strategic Fund I Venbio, Jonathan Young, Kevin Bitterman, Seth Loring Harrison, Skorpios Trust, Timothy Rolph and William Richard White.
View institutional ownership trends
.

How do I buy shares of Akero Therapeutics?

Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akero Therapeutics' stock price today?

One share of AKRO stock can currently be purchased for approximately $37.45.

How much money does Akero Therapeutics make?

Akero Therapeutics (NASDAQ:AKRO) has a market capitalization of $1.76 billion. The company earns $-112,030,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis.

How can I contact Akero Therapeutics?

Akero Therapeutics' mailing address is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.akerotx.com. The company can be reached via phone at (650) 487-6488 or via email at akero@sternir.com.

This page (NASDAQ:AKRO) was last updated on 3/27/2023 by MarketBeat.com Staff